pharma · Schizophrenia · Narcolepsy Type 1
Alkermes Pharma Ireland
Alkermes Pharma Ireland is a pharma organization headquartered in Dublin, IE. Primary therapeutic focus areas include Schizophrenia, Narcolepsy Type 1, Narcolepsy Type 2, Narcolepsy Type 1, Type 2 and Idiopathic Hypersom
Dublin, USA HQ
27 Employees
EMA registrant Type
Company details
- Status
- Public
- HQ
- Dublin, USA
- Employees
- 27
- Programs
- 6
- Drugs
- 3
- Patents
- 25
ALKS 2680-301
Phase 3 · small molecule · Narcolepsy Type 1, Type 2 and Idiopathic Hypersomnia
ALKS 2680-301 for Narcolepsy Type 1, Type 2 and Idiopathic Hypersomnia is a Phase 3 program (small_molecule) at Alkermes Pharma Ireland with 1 ClinicalTrials.gov record(s).
Internal code ALKS 2680-301
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Alkermes Pharma Ireland
- Phase
- Phase 3
- Modality
- small_molecule
- Indication
- Narcolepsy Type 1, Type 2 and Idiopathic Hypersomnia
- Status
- active
- Trials
- 1